C-MET is influenced by NRAS mutations, as NRAS-mutated melanomas, for instance, show higher activation of the C-MET pathway and increased sensitivity to C-MET inhibitors compared to BRAF (human gene that encodes a protein called B-Raf) mutated or wild-type melanomas. This evidence concerns the gene BRAF and melanoma.